Company Focus
Moderna
Latest Moderna News
Biotechnology
A staggering 800% increase in licensing agreement deal values for messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals was recorded over 2019 to 2024 year-to-date (YTD), driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. 16 October 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Pharmaceutical
Rivus Pharmaceuticals, a clinical-stage drug developer based in Virginia and California, announced that its Phase IIa HuMAIN trial met its primary endpoint of weight reduction. 14 August 2024
Generics
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
Pharmaceutical
An Expert View from the new chief executive of Gavi, the Vaccine Alliance, Sania Nishtar. 13 August 2024
Pharmaceutical
Swiss drugmaker Santhera Pharmaceuticals today announced the closing of two financing agreements that provided the company with gross funding totaling around 69 million francs ($80.2 million). 13 August 2024
Biotechnology
SpyBiotech, a UK biotech with a novel vaccine platform technology that can target infectious diseases, cancer and chronic diseases, has appointed Prakash Bhuyan as chief medical officer (CMO). 12 August 2024
Pharmaceutical
In a major boost to the domestic pharmaceutical industry, the Indian government has approved the manufacture of eight orphan drugs. 12 August 2024
Biotechnology
Last week’s news included second quarter financial results from BioNTech, the German mRNA biotech behind the successful covid vaccine Comirnaty, along with an update on its R&D pipeline. On the deal-making front, US biotech Equillium announced progress for its graft-versus-host disease drug itolizumab that is partnered with Japan’s Ono Pharmaceutical. Also, US gene editing firm Sangamo signed a licensing deal with Roche subsidiary Genentech that could earn it more than $2 billion. M&A news saw US firm Recursion enter a merger agreement with the UK’s Exscientia. Eli Lilly reported second quarter financial that beat expectations, driven by the performances of its new diabetes and obesity drugs. 11 August 2024
Pharmaceutical
The US Food and Drug Administration approved neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis). 10 August 2024
Biotechnology
Avidity Biosciences saw is shares close up more than 12% at $46.95, after it announced positive AOC 1044 5mg/kg data demonstrated unsurpassed delivery of phosphorodiamidate morpholino oligomers (PMO) concentrations to skeletal muscle in Duchenne muscular dystrophy (DMD) patients. 10 August 2024
Pharmaceutical
US biopharma Apellis Pharmaceuticals and partner Swedish Orphan Biovitrum have announced positive topline results from the Phase III VALIANT study. 9 August 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze